Pu, Minya
Messer, Karen
Davies, Sherri R.
Vickery, Tammi L.
Pittman, Emily
Parker, Barbara A.
Ellis, Matthew J.
Flatt, Shirley W.
Marinac, Catherine R.
Nelson, Sandahl H.
Mardis, Elaine R.
Pierce, John P.
Natarajan, Loki http://orcid.org/0000-0001-5719-828X
Funding for this research was provided by:
National Cancer Institute (R01CA166293, P30CA023100, F32CA220859)
Article History
Received: 4 September 2019
Accepted: 12 September 2019
First Online: 21 September 2019
Compliance with ethical standards
:
: SD has stock or other ownership in NanoString Techologies. BAP has a consulting or advisory Role with Bioalta; Research Funding from Genetech, Glaxo Smith Kline, and Novartis; and Patents, Royalties, Other Intellectual Property with Salk Institute Licensed Technology. MJE has a leadership role, Employment of Immediate Family Member, and stock or other ownership, consulting or advisory role, and Honoraria with Bioclassifier, Prosigna, and NanoString Technologies. ERM has a leadership role and stock with Qiagen N.V., and a consulting or advisory role with Regeneron. The remaining authors declare no conflict of interest.
: For The Women’s Healthy Eating and Living (WHEL) Study, we obtained IRB approval from participating institutions, and written informed consent from all participants, including for genomic analyses. All aspects of this study was approved by the Institutional Review Board at University of California, San Diego. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.